[Acquired platelet function disorders: pathogenesis, classification, frequency, diagnosis, clinical management].
Given the high consumption of pharmacological agents in western societies, it is not surprising at all that drugs represent the most common cause of acquired platelet dysfunction. While acetylsalicylic acid, clopigogrel and integrin alphaIIbbeta3 (GPIIb-IIIa) receptor antagonists are well-known as prototypes of antiplatelet drugs, other widely used agents including non-steroidal anti-inflammatory drugs, antibiotics, serotonin reuptake inhibitors, and volume expanders can also impair platelet function and cause or aggravate haemorrhages. Besides pharmacological agents, certain clinical conditions are often associated with qualitative platelet disorders and bleeding diathesis. Consequently, in contrast to inherited platelet disorders, acquired platelet function defects are much more frequent in clinical practice and deserve special attention. Their pathogenesis is widespread and heterogeneous with various, sometimes overlapping abnormalities. Moreover, acquired platelet dysfunctions can occur at any age and range in severity from mild to life-threatening haemorrhages. Due to their heterogeneity, acquired platelet function disorders will be classified and discussed according to the underlying clinical setting or disease.
Scharf
R E
RE
Institut für Experimentelle und Klinische Hämostaseologie, Hämotherapie und Transfusionsmedizin, Universitätsklinikum Düsseldorf, Biologisch-Medizinisches Forschungszentrum der Heinrich-Heine-Universität, Düsseldorf. rscharf@uni-duesseldorf.de
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D001241:Aspirin / Q000009:adverse effects; D001791:Blood Platelet Disorders / Q000139:chemically induced / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy; D001792:Blood Platelets / Q000502:physiology*; D003327:Coronary Disease / Q000097:blood / Q000628:therapy; D006470:Hemorrhage / Q000139:chemically induced / Q000209:etiology; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology; D020141:Hemostatic Disorders / Q000139:chemically induced / Q000209:etiology; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications; D009203:Myocardial Infarction / Q000097:blood / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects; D051437:Renal Insufficiency / Q000097:blood / Q000150:complications; D013921:Thrombocytopenia / Q000097:blood
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin